Talks at GS Alnylam’s Yvonne Greenstreet on RNAi and a ‘golden era’ in biotech
11 snips
May 29, 2025 Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, has over 25 years of biopharma experience and is a leader in RNA interference therapeutics. She discusses the transformative power of RNAi technology and highlights the approval of six new medicines in just six years. Greenstreet shares her vision for biotech, emphasizing a patient-focused, teamwork-oriented culture and the importance of diversity in leadership. She also reflects on her career journey, emphasizing mentorship’s role in developing future leaders and fostering innovation in the industry.
AI Snips
Chapters
Transcript
Episode notes
RNAi's Therapeutic Breakthrough
- RNA interference (RNAi) is a natural mechanism that can silence disease-causing proteins at the mRNA level.
- Alnylam overcame major delivery challenges to develop six RNAi medicines targeting the liver in six years.
RNAi’s Vast Potential Genome-wide
- RNAi can target 100% of the genome, unlike small molecules or biologics that address about 25%.
- Alnylam is expanding from rare genetic diseases to common ones like hypertension and CNS disorders using RNAi.
Set Bold Quantified Goals
- Set bold, quantitative five-year goals to align and focus the company’s efforts.
- Combine product launches, pipeline growth, and profitability targets to become a top biotech.